By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Hookipa: EUR 50 million for immunotherapy against cancer

© Hookipa Biotech

A vaccination against the Cytomegalovirus ("CMV"), which is a herpesvirus, should be tested on patients undergoing organ transplants. In addition, immunization therapy is to be tested on patients with head and neck squamous cell carcinoma. Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Meet us @ BIO-Europe

    25.10.2021 - 28.10.2021/ 07.30am - 06.00pm, Virtual Event

Austria Map

Find the perfect location for your company

Vienna is a beautiful city and a natural place to be for Trask. We are happy that we can introduce our great technology expertise together with revolutionary ready-to-use solutions to Austrian banks. And thanks to the cooperation with ABA everything is a bit easier.

Daniel Pecina, CEO Trask Austria GmbH

trask logo
More testimonials

news from the business location Austria

Austria stands out due to its tax incentives for research

You want to know why companies such as Infineon, Siemens and Bosch have been carrying out research in Austria for decades? Contact us.

Lynus – the software for the enegery-optimized building of the future.

The business location Austria offers innovative businesses such as Lynus the right platform, a modern environment, and highly skilled workforce in order to use complex IOT solutions with ease. Additionally the desire of a lot of Austrian companies to minimize their CO2 footprint in a sustainable way, appeals very much to our business model.

More news All blog posts